Enzo Biochem, Inc.

Equities

ENZ

US2941001024

Biotechnology & Medical Research

Market Closed - Nyse 04:00:02 2024-04-19 pm EDT 5-day change 1st Jan Change
1.09 USD -3.54% Intraday chart for Enzo Biochem, Inc. -6.84% -21.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Inflation Worries Continue to Weigh on Mood DJ
Enzo Biochem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 CI
Enzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive Officer CI
Enzo Biochem, Inc. Appoints Patricia Eckert as Chief Financial Officer CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight DJ
North American Morning Briefing : Stock Futures Edge Up to Start the Week DJ
Enzo Biochem, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023 CI
North American Morning Briefing : Traders Await -2- DJ
North American Morning Briefing : Investors Weigh -2- DJ
Enzo Biochem, Inc. Reports Earnings Results for the Full Year Ended July 31, 2023 CI
Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of Directors CI
North American Morning Briefing : Amazon, Intel -2- DJ
North American Morning Briefing : Bond Yields, -2- DJ
North American Morning Briefing : Stock Futures Point Lower Ahead of Big Bank Earnings DJ
Enzo Biochem Chief Executive Hamid Erfanian Departs MT
Enzo Biochem Announces Departure of Hamid Erfanian from the Board of Directors CI
Enzo Biochem, Inc. Announces CEO Changes CI
Top Premarket Gainers MT
Enzo Biochem Completes Deal to Sell Clinical Laboratory Division to Laboratory Corp. of America for $113.3 Million MT
North American Morning Briefing : Traders Digest -2- DJ
Enzo Biochem, Inc. Reports Revenue Results for the Third Quarter Ended April 30, 2023 CI
Enzo Biochem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023 CI
North American Morning Briefing : Nasdaq Futures Slip as Rate Rise Fears Weigh DJ
Enzo Biochem, Inc. announced that it expects to receive $7.608696 million in funding from JGB Collateral, LLC CI
Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027 CI
Chart Enzo Biochem, Inc.
More charts
Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.
More about the company
  1. Stock Market
  2. Equities
  3. ENZ Stock
  4. News Enzo Biochem, Inc.
  5. MT Newswires After Hours Watch List: ENZ, ISUN, SLDB